Filter
Period
Filter by
recent search
Showing: 1 – 05 of 152 Regulated Information
Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio
PARIS, FRANCE, 3 March 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) today announced it has completed the acquisition of Albireo Pharma, Inc., a leading innovator in bile-acid modulators to treat rare liver conditions. The acquisition enriches Ipsen’s Rare Disease portfolio, with…
Voting rights on 31 January 2023
This article or press release has no online content. Please download the associated documents for more information.
Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023
PARIS, FRANCE, 22 February 2023 – Ipsen S.A. (Euronext: IPN; ADR: IPSEY) today announced that Anemone Acquisition Corp. (Purchaser), its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued…
IPSEN: Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares composing the share capital